Lexeo Therapeutics reports 2026 annual meeting results; all director nominees elected

Lexeo Therapeutics, Inc.

Elected Class III directors Townsend (64.7M FOR), Cooperstone (48.8M FOR), and Cholmondeley (64.7M FOR); broker non-votes ~10M each.
Ratified KPMG as independent auditor for fiscal 2026: 75.5M FOR, 55.6K AGAINST, 30.1K abstain.
Annual Meeting held virtually on June 25, 2026.

item 5.07

Lexeo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-288703

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.